July 18, 2023 10:59 AM EDT
News Briefing

Aridis to delist from Nas­daq; Bi­cy­cle clos­es $200M+ of­fer­ing

Paul Schloesser

Associate Editor

Aridis Phar­ma­ceu­ti­cals is be­ing tak­en off the Nas­daq, ef­fec­tive Wednes­day.

The biotech re­port­ed the news in an SEC fil­ing Mon­day, say­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times